Background. Controversy continues regarding the use of adjuvant radiation therapy (RT) and hormonal therapy (HT) for patients undergoing breast-conserving therapy (BCT) for ductal carcinoma in situ (DCIS). Methods. A prospective database was queried to identify women 18 years of age or older treated for DCIS from 2002 to 2013. Results. BCT was completed for 300 patients with a median age of 66 years. The median DCIS size was 0.7 cm (range 0.1-6.0 cm). The DCIS grades were high (44 %), intermediate (37 %), and low (19 %). The closest margin was wider than 3 mm in 80 % and wider than 5 mm in 63 % of the cases. Adjuvant RT was administered to 183 patients (61 %), and the RT status of 9 patients (3 %) was unknown. RT was associated with age, DCIS size, comedo necrosis, grade, and treatment in 2002-2007 versus 2008-2013. Adjuvant HT was administered to 86 estrogen receptor-positive patients (39 %), and the HT status of 4 patients (2 %) was unknown. The median follow-up period was 63 months (range 4-151 months). The 5-year overall local recurrence (LR) rate was 4 % (95 % confidence interval [CI] 2.1-7.4 %). The 5-year LR rate was 3.9 % (95 % CI 1.8-8.6 %) for the RT patients and 4.1 % (95 % CI 1.6-10.7 %) for the patients not receiving RT. Of 13 LRs, 10 (77 %) were DCIS, and 3 (23 %) were invasive including one node-positive recurrence. Conclusions. Multidisciplinary and joint decision making in the treatment of DCIS results in a substantial and increasing number of patients forgoing adjuvant RT, adjuvant HT, or both. Reasonable 5-year LR rates suggest that such decision making can appropriately allocate patients to adjuvant therapies.
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Ductal carcinoma in situ (DCIS) diagnoses have been increasing since the advent of mammographic screening, 1 and the use of breast-conserving therapy (BCT) for DCIS also has increased over time. 2 Despite this volume of experience, the application of adjuvant radiation therapy (RT) and adjuvant hormonal therapy (HT) to patients undergoing BCT for DCIS has not been standardized.
Randomized clinical trials have demonstrated that RT as a part of BCT for DCIS reduces the risk of local recurrence (LR) by approximately 50 %, albeit with no survival advantage. [2] [3] [4] [5] [6] Similarly, randomized clinical trials have shown that adjuvant tamoxifen reduces the risk of all breast cancer events (ipsilateral plus contralateral) by approximately 30 %, also with no clear survival advantage. 5, [7] [8] [9] Nonetheless, a substantial proportion of patients are treated with lumpectomy alone. 10, 11 Many patients and physicians seek to avoid adjuvant treatments due to potential adverse effects, time and travel demands, lack of demonstrable survival benefit, and costs. Despite the multiple randomized trials cited earlier, available evidence argues both for and against the use of adjuvant RT. 12, 13 Intergroup (Eastern Cooperative Oncology Group and North Central Cancer Treatment Group) trial E5194 enrolled patients with low-or intermediategrade DCIS (B2.5 cm, group 1) or high-grade DCIS (B1 cm, group 2) with margin widths 3 mm or greater into a prospective trial of no adjuvant RT and found that with a median follow-up period of 6.2 years, the 5-year LR rate in group 1 was 6.1 %, suggested to be low enough for omission of RT to be considered for such patients. 14 The recent Radiation Therapy Oncology Group (RTOG) 9804 study reported that at a median of 7 years, good-risk DCIS patients (unicentric low/intermediate grade, \2.5 cm) had an LR rate of 6.7 % when randomized to no RT versus 0.9 % when randomized to RT. 15 The National Comprehensive Cancer Network guidelines (www.nccn.org) include lumpectomy without RT as an alternative category 2B recommendation ''if the patient and physician view the individual risk as 'low','' and recommend that adjuvant HT with tamoxifen be ''considered'' postoperatively but that ''since a survival benefit has not been demonstrated, individual consideration of risks and benefits is important.'' Thus, significant latitude in the decision making exists for the application of adjuvant RT and HT to individual patients with DCIS.
At our institution, decisions regarding adjuvant RT and HT for patients undergoing BCT for DCIS are made by a multidisciplinary team in a shared way (i.e., with significant education of each patient allowing for considerable patient influence on these decisions). Such collaborative decision making has the potential to provide the best outcomes by matching the available evidence to each patient's unique clinical circumstances and goals. However, the outcomes of such decision making have not been well studied and are of interest for establishing the effectiveness of such a model. This study was undertaken to examine the rates of adjuvant RT and HT with such decision making and the outcomes of these patients.
METHODS
After obtaining institutional review board approval, a prospective breast database and institutional cancer registry were queried to identify women treated for DCIS with BCT between January 2002 and December 2013. Medical records were reviewed to supplement and verify the database information. Clinical records were examined to determine the physician team recommendations regarding each adjuvant therapy and the patient response. Margin status was characterized by the closest measurement from DCIS to an inked surface and categorized as positive, negative without measurement, negative but \1, 1-1.9, 2-2.9, 3-4.9, 5 mm or greater, or 10 mm or greater. Not all margins were measured if larger than 5 mm, so some patients reported as having margins greater than 5 mm may have had margins greater than 10 mm. Our institutional approach is to consider margins 2 mm or wider as adequate for DCIS, so patients with a margin less than 2 mm routinely underwent a re-excision.
Demographic and clinical characteristics were summarized between those receiving and those not receiving adjuvant RT. Local recurrence and overall survival rates were calculated at 5 years using the Kaplan-Meier method.
Time to LR was calculated as time from diagnosis to first LR. Overall survival was calculated as time from diagnosis to death due to any cause. A patient was censored at the last follow-up date if the specified event had not been observed.
Univariable logistic regression was used to investigate variables associated with the receipt of RT. Variables significant at a p value lower than 0.05 were included in a multivariable logistic regression model. This multivariable logistic regression model was used to obtain individual propensity scores. The propensity score then was included as a continuous variable in a Cox proportional hazards regression model of local recurrence rate to estimate the hazard ratio for adjuvant RT relative to no RT. For analysis, SAS version 9.3 (Cary, NC, USA) was used.
RESULTS
For this study, 471 patients treated for DCIS were identified, 313 (66 %) of whom underwent attempted BCT. Subsequently, 13 patients (4 %) underwent conversion to mastectomy due to extensive DCIS, leaving 300 patients who completed BCT as the focus of this study. The median age was 66 years (range 38-89 years), and 92 % of the patients were Caucasian. The mean DCIS size was 1 cm, and the median size was 0.7 cm (range 0.1-6.0 cm). No size was recorded for 13 patients (4 %). The grades of DCIS were high (44 %), intermediate (37 %), and low (19 %). The study cohort included 39 patients (13 %) with multifocal DCIS and 198 patients (66 %) with comedo necrosis. Of 269 patients whose estrogen receptor (ER) status had been determined, 221 (82 %) were ER-positive. Preoperative breast magnetic resonance imaging (MRI) was obtained for 39 patients (13 %). The final margins were pathologically negative for all the patients. Re-excision of margins at a second operation was required for 26 patients (9 %). The final closest margin width among the 93 % with a measured distance was 2 mm or greater in 98 %, 5 mm or greater in 69 %, and 10 mm or greater in at least 22 % of the patients.
Of the 300 BCT patients, 183 (61 %) underwent adjuvant RT, with the RT status of 9 patients (3 %) unknown. The rate of adjuvant RT decreased from 70 % during 2002-2007 to 57 % during 2008-2013. Among the patients who did not receive RT, RT was offered or recommended but declined by 74 %, RT was not recommended for 23 %, and one patient each (1 %) had prior radiation exposure, became too ill to receive RT, or had no identifiable target for surgery or RT after core biopsy. Among the patients not undergoing adjuvant RT, all had a modified Van Nuys index 16 score of 5 or lower (18 % = 3; 55 % = 4; 28 % = 5). Of these no-RT patients, 59 (55 %) met the E5194 group 1 criteria and another 18 (17 %) met the E5194 group 2 criteria.
The characteristics of the patients who received adjuvant RT and those that did not are presented in Table 1 . In the univariable logistical regression analysis, receipt of RT was significantly associated with younger age, comedo necrosis, larger DCIS, higher grade, and earlier period (2002-2007 vs. 2008-2013) . Margin width, multifocal disease, use of MRI, and re-excision of margins were not significantly associated with receiving RT (Tables 2 and  3 ). Among all the BCT patients, 99 (33 %) underwent adjuvant HT, with the HT status of 6 patients (2 %) unknown. Of the 221 ER-positive BCT patients, 86 (39 %) underwent adjuvant HT, with the HT status of 4 patients (2 %) unknown. The treatment strategies used for the patients in the cohort are summarized in Fig. 1 .
The median follow-up period was 63 months (range 4-151 months), including 74 months for the RT patients, 48 months for the no-RT patients, and 58 months for the RT status unknown patients. The 5-year LR rate was 4 % (13 events; 95 % CI 2.1-7.4 %) overall. No regional or distant recurrences were observed. For the RT patients, the 5-year LR rate was 3.9 % (95 % CI 1.8-8.6 %). For the patients not receiving RT, the 5-year LR rate was 4.1 % (95 % CI 1.6-10.7 %, Fig. 2) .
The risk of LR after adjustment for patient and tumor factors (age, comedo necrosis, DCIS size, grade, hormone therapy, and time period, Table 3 ) was not associated with receipt of RT, but the confidence intervals were wide (hazard ratio [HR] 0.59; 95 % CI 0.15-2.31; p = 0.45). The 5-year LR rate was 5.7 % (95 % CI 2.2-14.6 %) for those who had RT recommended or offered but patient declined the treatment, whereas no LRs were observed among 23 patients for whom RT was not recommended or among eight patients who had miscellaneous reasons why RT was not administered. The 5-year LR rate was 4.8 % (95 % CI, 0.7-29.3 %) for the patients who underwent a re-excision for margins smaller than 2 mm. The 5-year LR rate for the 274 patients who did not require re-excision of margins was 3.9 % (95 % CI 2.0-7.5 %).
Of the 13 LRs, 11 (85 %) were in the same quadrant of the breast, 10 (77 %) were recurrences of DCIS, and 3 (23 %) were invasive recurrences including 1 (8 %) nodepositive recurrence. The recurrences were treated with repeat BCT in five patients (38 %) (all of whom had not undergone adjuvant RT) and mastectomy in eight patients (62 %) (all of whom had undergone adjuvant RT). The patient with a node-positive recurrence was the only patient treated with adjuvant cytotoxic chemotherapy. The overall survival rate at 5 years was 95 % (95 % CI 90.6-97.0 %). No deaths were attributed to breast cancer.
DISCUSSION
Ideally, individualized medical care identifies the best evidence-based treatments as assessed by a multidisciplinary care team for their applicability to an individual patient, presents these in an understandable way to each patient, and applies the options aligned with the treatment goals and priorities of each patient. The treatment of DCIS presents several decision points at which valid arguments exist for opposite sides of a given decision, especially regarding the ''aggressiveness'' of adjuvant treatment. Thus, if multidisciplinary shared decision making is applied in an individualized fashion for DCIS, it should be expected that some patients will choose adjuvant RT and/or adjuvant HT based on a higher perceived risk of recurrence or a prioritization of minimizing recurrence risk, whereas others will decline such therapy based on a lower perceived risk of recurrence or a prioritization of avoiding additional therapies.
In the current cohort, with this model of decision making, 61 % of the patients treated with BCT proceeded with adjuvant RT, and 39 % of the ER-positive patients proceeded with adjuvant HT. The 61 % rate of adjuvant RT is slightly higher than in previous reports on large groups of DCIS patients. 10, 11 The 39 % rate of HT in the current study matches the rate reported in another cohort. 17 The rates of adjuvant RT declined during the period of this study, suggesting that patients, providers, or both are recognizing more clinical circumstances that suggest a risk of recurrence sufficiently low to warrant forgoing RT and prioritizing simplified therapy.
Additional resources for assessing the risk of recurrence and the utility of RT for such patients include the DCIS Oncotype DX test (Genomic Health, Inc., Redwood City, CA) 18 and a free online nomogram. 19 We have used these tools only rarely when patients have had a difficult time with their decision regarding adjuvant RT.
It is well established that adjuvant RT lowers the LR risk among patients treated for DCIS. The fact that the 5-year LR rates for the patients in this study were similar among those undergoing RT (3.9 %) and those not undergoing RT (4.1 %) should not be taken to suggest otherwise. These rates, useful only as observations rather than for comparison, instead show that those allocated to no RT were at lower risk for LR. This is consistent with the findings of a univariable logistical regression analysis showing that younger patients with large tumor size, higher grade, and presence of comedo necrosis (all known risks OR odds ratio, CI confidence interval, DCIS ductal carcinoma in situ for LR) were more likely to receive RT. This assessment is further bolstered by the fact that all the patients who experienced an LR received the recommendation not to undergo adjuvant RT. Although margin width was not associated with receipt of RT, 80 % of the patients in the current study had a closest margin wider than 3 mm (as called for in E5194), and 63 % had a closest margin wider than 5 mm. This large proportion of patients with a relatively wide margin may therefore have obscured any statistical evidence of its consideration in RT decision making. Overall, these LR rates suggest that multidisciplinary shared decision making can be applied in an appropriate and safe manner for patients with DCIS.
The 5-year LR rates of approximately 4 % for both the RT and no RT patients in this cohort are comparable with those of other studies. Trial E5194 demonstrated a 5-year LR rate in group 1 (low/intermediate-grade stratum) of 6.1 %, 14 and a retrospective analysis of patients treated with RT who met the E5194 criteria found a LR rate of 4.4 % after 7 years in the low/intermediate-grade cohort and 2 % in the high-grade cohort. 17 It is worth remembering that even good-risk DCIS patients have their LR risk reduced by the addition of adjuvant RT. 15 Therefore, all patients with DCIS, regardless of estimated LR risk, should be educated about the option of RT and its ability to lower LR risk even further.
No deaths in the current cohort were attributed to disease, but this is of little value as an outcome measure during a median follow-up period of only 63 months for DCIS patients. Among those who did experience a recurrence, only 23 % had invasive recurrences, and only 8 % had node-positive recurrences (n = 1, 0.3 % of the entire cohort). Others have likewise reported that one third or less of recurrences were invasive disease. 20 Some limitations of this study should be acknowledged. The multidisciplinary shared decision making for the patients in this cohort was performed at a highly integrated National Cancer Institute-designated Comprehensive Cancer Center site, so the applicability of this model to other types of practice settings cannot be determined. This study also was limited by a relatively small sample size, which may obscure small but significant differences from the results presented here. A propensity score method was used to help compensate for the low number of events in this cohort, but with only 13 local recurrences observed, our statistical power to conduct multivariable analysis and adjust for all the factors influencing LR was limited. This study is useful for observing the practice patterns and 5-year LR rates with this method of decision making but not for determining factors influencing LR that have been well documented in larger cohorts. Finally, the median follow-up time of 63 months was adequate for indicating reliable 5-year LR rates, but whether these rates will rise significantly over time will require monitoring. Furthermore, this follow-up period was too short for a reliable determination of disease-specific and overall survival for patients with DCIS.
CONCLUSION
Shared multidisciplinary decision making in the treatment of DCIS patients results in two thirds of patients undergoing breast-conserving surgery, with a substantial and increasing minority forgoing adjuvant RT and a majority forgoing adjuvant HT. Patients allocated to these treatment strategies have reasonable 5-year LR rates whether receiving RT or not. Thus shared multidisciplinary decision making for patients with DCIS is an effective strategy for individualized therapy.
